But that's no side effects from a single dose right?
Do they not need safety data from participants who take multiple doses across a period of weeks?
It seems like this type of study is needed to answer the question of whether there are side effects associated with more regular use (i.e. how they intend it to be used in the real world).
Also, does anyone know any further details about why SDS cracked the code to nasal administration then sold the rights to LTR Pharma? Why would they do this?
Also they sold it to LTR Pharma in a licensing deal according to a previous presentation. Does that mean there is royalty sharing? Does any know more about this?
Ann: SPONTAN achieves positive clinical study results, page-118
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.98 |
Change
-0.025(1.25%) |
Mkt cap ! $167.4M | |||
| Open | High | Low | Value | Volume |
| $1.99 | $2.03 | $1.91 | $1.612M | 815.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.99 | 7000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| LTP (ASX) Chart |